Buprenorphine Versus Methadone in 105,000 Patients: Fewer Overdoses, More Mood Disorders

This large TriNetX propensity score-matched analysis gives pharmacists real-world comparative signals on overdose, infection, cardiometabolic and psychiatric outcomes for the two first-line opioid agonist therapies, with substantial caveats about confounding.

📅 Journal publication: Oct 9, 2026 · Last updated: Oct 23, 2026

buprenorphinemethadoneopioid agonist therapymedication-assisted treatmentopioid use disorderpropensity score matchingTriNetXreal-world evidenceoverdosecardiometabolic riskinfectionsretrospective cohort Behavioral Health / Addiction Medicine

Background Information

Buprenorphine shows metabolic benefits over methadone in opioid treatment.

Buprenorphine and methadone are key treatments for opioid use disorder (OUD), with differing safety and efficacy profiles. Buprenorphine was linked to lower risks of diabetes, metabolic syndrome, stroke, sepsis, and overdoses but higher risks of alcohol use disorder and cannabis use disorder compared to methadone. The study highlights the need for individualizing OUD treatments based on patient-specific risks and monitoring for comorbid conditions. Buprenorphine may offer metabolic and overdose safety advantages over methadone but requires careful monitoring for mental health issues.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Elman I, Albanese M, Panchal K, Ramsey KM, Elman DJ, Ramsey DJ

Citation: Elman I, Albanese M, Panchal K, et al. Comparative health outcomes of buprenorphine versus methadone treatment for opioid use disorder: a retrospective propensity score-matched cohort study in the global federated electronic health record network. BMJ open. 2026;16(10):e122747. doi:10.1136/bmjopen-2026-122747

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →